Our Vision in Action
Wholly-owned programs
inCerebro Drug discovery institute currently has four drug discovery pipelines (May 2020). These four pipelines aim to develop anti-cancer agents, cancer metastasis inhibitors, immunotherapy, and skin treatments. We aim to release the pre-clinical results of the main pipeline, ICRB-001, this year, and we will continue to add pipelines for the development of first-in-class drugs.
| Pipelines | Target validation | Hit generation | Lead identification | Lead optimization | Pre-clinical development | Clinical trials | |
|---|---|---|---|---|---|---|---|
 |
ICRB-001 GPCR Anti-Cancer |
||||||
ICRB-002 IPF Drug Discovery |
|||||||
ICRB-501 Anti-colon Cancer |
|||||||
ICRB-502 Anti-breast Cancer |
|||||||
ICRB-503 AML Drug Discovery |
Collaborative Programs
We currently have over three collaborative programs, including confidential programs.
| Collaborator | Pipelines | etc |
|---|---|---|
 |
ICRB-501 |
… |
 |
ICRB-502 ICRB-503 |
… |